ProCE Banner Activity

Phase I/II Trial of Mezigdomide + Dexamethasone in R/R MM: Preliminary Results From the Dose-Expansion Phase II Cohort

Slideset Download
Conference Coverage

In the dose-expansion cohort of a phase I/II trial, mezigdomide + dexamethasone showed promising efficacy with a manageable safety profile in patients with triple-class refractory relapsed/refractory multiple myeloma.

Released: December 19, 2022

Expiration: December 18, 2023

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen